Skip to content

Microdosing research published in 2025

Page 3 of 3: studies 41 to 50 of 50, newest first. Back to the microdosing overview

Studies

Multimodal creativity assessments following acute and sustained microdosing of lysergic acid diethylamide.

Psychopharmacology February 1, 2025 Robin J Murphy, Rachael Sumner, Kate Godfrey et al. 9 citations

Enhanced creativity is often cited as an effect of microdosing (taking repeated low doses of a psychedelic drug). There have been recent efforts to validate the reported effects of microdosing, however creativity remains a difficult construct to quantify. The current study aimed to assess microdosing's effects on creativity using a multimodal battery of tests as part of a randomised controlled...

Application of microarray patches for the transdermal administration of psychedelic drugs in micro-doses.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V February 1, 2025 Octavio E Fandiño, Aaron R J Hutton, Chunyang Zhang et al. 4 citations

Throughout history, psychedelic compounds have been used for religious, spiritual and recreational purposes. A plethora of studies have reported the use of psychedelic compounds in the treatment of various conditions, such as alcoholism, addictions, depressive state to borderline schizophrenia, personality disorder, among other mental disorders. Psychedelic microdosing, a common technique in...

Notes from the Field: Severe Health Outcomes Linked to Consumption of Mushroom-Based Psychoactive Microdosing Products - Arizona, June-October 2024.

MMWR Morbidity and Mortality Weekly Report January 9, 2025 Heather L. Walker, Maureen Roland, Steven Dudley et al. 1 citation

In June 2024, Arizona Department of Health Services (ADHS) was notified by Arizona's poison control centers (PCCs)* of adverse health outcomes occurring after ingestion of a Diamond Shruumz-brand product containing proprietary blends of mushroom extracts and adaptogens.† These products were sold as chocolate bars, gummies, and cones and could be purchased online or at local retailers...

Effects of fertilizer microdosing on soil phosphorus and sulphur availability to Solanum macrocarpon in Southwest Nigeria

Journal of Agricultural Sciences, Belgrade 2025 Ifeoluwa Oluwaponle, Francis Olatoberu, Mary Idowu et al.

This present study aimed at evaluating the effect of fertilizer rate and time of application on yield, and determined the availability of soil P and S to S. macrocarpon. The experiment was conducted in the derived savanna (Ogbomoso) and the rainforest (Ilesha) in southwest Nigeria. The treatments were arranged in a factorial combination and laid out in a split-plot design with four replicates....

Optimizing yield, nitrogen uptake and nitrogen use efficiency in fluted pumpkin through fertilizer microdosing

Journal of Agricultural Sciences, Belgrade 2025 Francis Olatoberu, Mary Idowu, Durodoluwa Oyedele et al.

Due to severely weathered soils and copious amounts of rainfall, the timing and rate of fertilizer application to enhance yields, nitrogen use efficiency, and recovery of fluted pumpkin (Telfairia occidentalis) have been key concerns in southwestern Nigeria. The experiment was conducted using a 2 x 2 x 5 randomized complete block split plot design (RCBSPD) with four varieties. Ilesa and...

Safety of Indocyanine Green Microdosing for Clinical Imaging of CSF Ventricular Dynamics and Extracranial Outflow.

Journal of neuroimaging : official journal of the American Society of Neuroimaging 2025 Miriam Zamorano, Banghe Zhu, Ahmed T Massoud et al.

Intravenous administration of indocyanine green (ICG) has been approved in brain surgeries for decades, yet concerns about neurotoxicity prevent its direct administration into the cerebrospinal fluid (CSF). Armed with prior animal studies demonstrating the feasibility of using ICG microdosing into the CSF, we sought to evaluate its nonclinical safety profile and obtain surrogate measures in...

DOI: 10.1111/jon.70028 (opens in new tab) Full text (opens in new tab) Brain injury Cervical lymphatics Indocyanine green Near‐infrared fluorescence +2

Emerging Risks of Amanita Muscaria: Case Reports on Increasing Consumption and Health Risks.

Acta medica Lituanica 2025 Emilija Savickaitė, Gabija Laubner-Sakalauskienė 4 citations

The increasing popularity of Amanita muscaria, driven by its hallucinogenic properties, has raised significant public health concerns, particularly as it remains largely unregulated across most European Union countries. The mushroom contains muscimol, a compound that induces euphoria, altered perception, and hallucinations, and its precursor, ibotenic acid, converts to muscimol when dried or...

Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry?

International review of neurobiology 2025 Iva Totomanova, Eline Haijen, Petra P M Hurks et al.

Clinical trials using full doses of psychedelics have provided preliminary evidence supporting their safety and efficacy in treating a variety of physical and psychological conditions. Anecdotal reports indicate that even very small amounts of these substances may provide therapeutic benefits, though robust clinical studies are still needed. This chapter reviews the current experimental studies...

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.

Neuropsychiatric Disease and Treatment 2025 Daniel A Kinderlehrer 13 citations

The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation underlies a significant subset of psychiatric conditions, particularly major depressive and anxiety disorders. Anti-inflammatory interventions have demonstrated benefit in these conditions. Psilocin, the active ingredient of mushrooms in the...

Treatment of neuropathic pain with repeated low-dose MDMA: a case report.

Frontiers in Psychiatry 2025 Peter Gasser, Matthias E. Liechti, Friederike Holze 2 citations

A 64-year-old male patient who suffered from traumatic life experiences and neuropathic pain after oncological chemotherapy was treated with medium to high doses of lysergic acid diethylamide (LSD) and high doses and microdoses of methylenedioxymethamphetamine (MDMA). At the beginning of treatment, the patient did not experience any acute subjective effects of LSD at a dose of 200 µg. After...